Gerald G.. Krueger
#140,977
Most Influential Person Now
Gerald G.. Krueger's AcademicInfluence.com Rankings
Gerald G.. Kruegerphilosophy Degrees
Philosophy
#7356
World Rank
#10560
Historical Rank
Logic
#4414
World Rank
#5703
Historical Rank
Gerald G.. Kruegerbiology Degrees
Biology
#9990
World Rank
#13266
Historical Rank
Genetics
#1039
World Rank
#1137
Historical Rank
Download Badge
Philosophy Biology
Gerald G.. Krueger's Degrees
- PhD Genetics University of California, Berkeley
- Doctorate Medicine University of California, San Francisco
Why Is Gerald G.. Krueger Influential?
(Suggest an Edit or Addition)Gerald G.. Krueger's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. (2007) (1107)
- Genomewide Scan Reveals Association of Psoriasis with IL-23 and NF-κB Pathways (2008) (1070)
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) (2008) (1056)
- The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. (2001) (1017)
- Psoriasis: epidemiology, clinical features, and quality of life (2005) (882)
- A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. (2007) (789)
- Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial (2005) (698)
- Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. (2001) (594)
- Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. (2009) (582)
- Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity (2012) (555)
- Psoriasis assessment tools in clinical trials (2005) (498)
- National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. (2008) (429)
- Identification of fifteen new psoriasis susceptibility loci highlights the role of innate immunity (2012) (397)
- Impact of obesity and smoking on psoriasis presentation and management. (2005) (375)
- Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. (2012) (325)
- A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. (2002) (323)
- The natural history of recurrent herpes simplex labialis: implications for antiviral therapy. (1977) (317)
- Genome-wide association analysis identifies three psoriasis susceptibility loci (2010) (314)
- Consensus on a core set of domains for psoriatic arthritis. (2007) (289)
- A classification of psoriasis vulgaris according to phenotype (2007) (278)
- Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). (2015) (276)
- A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. (2004) (268)
- A randomized trial of etanercept as monotherapy for psoriasis. (2003) (256)
- Psoriasis--recent advances in understanding its pathogenesis and treatment. (2005) (253)
- Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture. (2015) (240)
- Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? (2000) (234)
- Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants (2016) (219)
- Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. (2007) (203)
- Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) (2016) (202)
- Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. (2012) (195)
- Fine Mapping Major Histocompatibility Complex Associations in Psoriasis and Its Clinical Subtypes (2014) (190)
- Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. (1998) (188)
- Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial (2006) (187)
- A double-blind evaluation of topical capsaicin in pruritic psoriasis. (1993) (182)
- Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. (1997) (171)
- Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci (2015) (167)
- Multiple Loci within the Major Histocompatibility Complex Confer Risk of Psoriasis (2009) (158)
- Consensus guidelines for the management of plaque psoriasis. (2012) (156)
- Obesity in early adulthood as a risk factor for psoriatic arthritis. (2010) (154)
- A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. (2012) (150)
- Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility (2015) (149)
- Patient‐reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial (2005) (135)
- Consensus workshop on the toxic effects of long-term PUVA therapy. (1998) (134)
- Epidemiology of psoriasis: clinical issues. (1994) (134)
- From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis (2017) (131)
- Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. (2003) (130)
- Percutaneous penetration in the hairless dog, weanling pig and grafted athymic nude mouse: evaluation of models for predicting skin penetration in man (1984) (130)
- Topical metronidazole maintains remissions of rosacea. (1998) (129)
- Genome-wide meta-analysis of Psoriatic Arthritis Identifies Susceptibility Locus at REL (2011) (120)
- From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. (2008) (120)
- Evaluation of human skin reconstituted from composite grafts of cultured keratinocytes and human acellular dermis transplanted to athymic mice. (1996) (119)
- AAD consensus statement on psoriasis therapies. (2003) (119)
- Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. (2003) (118)
- Genetics of psoriasis and psoriatic arthritis: update and future direction. (2008) (114)
- Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study) (2014) (111)
- Response to injury of skin involved and uninvolved with psoriasis, and its relation to disease activity: Koebner and‘reverse’Koebner reactions (1982) (110)
- Long-term maintenance of psoriatic human skin on congenitally athymic (nude) mice. (1975) (106)
- microRNAs in Psoriasis. (2016) (105)
- Treatment of condyloma acuminatum with three different interferons administered intralesionally. A double-blind, placebo-controlled trial. (1988) (103)
- International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. (2009) (102)
- Development and use of alefacept to treat psoriasis. (2003) (102)
- Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. (2013) (100)
- The effect of hair color on the incorporation of codeine into human hair. (2003) (100)
- Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis. (2004) (97)
- Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study (2012) (94)
- Involved and uninvolved skin from psoriatic subjects: are they equally diseased? Assessment by skin transplanted to congenitally athymic (nude) mice. (1981) (93)
- Genome-wide scan reveals association of psoriasis with IL-23 and NFB pathways (2016) (93)
- CTLA 4 Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris (1999) (92)
- Clinical features of psoriatic arthritis. (2002) (91)
- Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis (2005) (89)
- Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. (2014) (88)
- The natural history of ultraviolet radiation-induced herpes simplex labialis and response to therapy with peroral and topical formulations of acyclovir. (1991) (88)
- Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking. (2009) (88)
- Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx. (1999) (86)
- An animal model of antibody binding in cutaneous lupus. (1986) (85)
- Patient satisfaction with treatments for moderate‐to‐severe plaque psoriasis in clinical practice (2014) (85)
- Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. (2012) (84)
- Further genetic evidence for three psoriasis-risk genes: ADAM33, CDKAL1, and PTPN22. (2009) (84)
- Site of action of cortisol in cellular immunity. (1973) (83)
- Hair growth in scalp grafts from patients with alopecia areata and alopecia universalis grafted onto nude mice. (1987) (81)
- Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. (2005) (81)
- Epstein-Barr virus as an etiological agent in the pathogenesis of lymphoproliferative and aproliferative diseases in immune deficient patients. (1985) (79)
- Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. (2006) (78)
- Definitions of measures of effect duration for psoriasis treatments. (2005) (77)
- Inflammatory and immune cell function in psoriasis--a subtle disorder I. In vivo and in vitro survey. (1978) (76)
- Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis. (2014) (76)
- Efficacy and safety of treatment modalities for psoriasis. (1998) (76)
- Alefacept therapy produces remission for patients with chronic plaque psoriasis (2003) (76)
- Variants in the 5q31 cytokine gene cluster are associated with psoriasis (2008) (74)
- Feasibility of Measuring the Bioavailability of Topical Betamethasone Dipropionate in Commercial Formulations Using Drug Content in Skin and a Skin Blanching Bioassay (2004) (74)
- Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo‐Controlled Study (2016) (74)
- Biology of Langerhans cells: selective migration of Langerhans cells into allogeneic and xenogeneic grafts on nude mice. (1983) (74)
- Selective targeting of T cell subsets: focus on alefacept – a remittive therapy for psoriasis (2002) (73)
- Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients (2018) (73)
- The effect of various sunscreen agents on skin damage and the induction of tumor susceptibility in mice subjected to ultraviolet irradiation. (1981) (71)
- Inflammatory and immune cell function in psoriasis: II. Monocyte function, lymphokine production. (1978) (71)
- Production of Sézary-like cells from normal human lymphocytes. (1975) (70)
- An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. (2005) (68)
- Observations of psoriasis in the absence of therapeutic intervention identifies two unappreciated morphologic variants, thin-plaque and thick-plaque psoriasis, and their associated phenotypes. (2006) (68)
- Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. (1991) (68)
- Genetic variations in cytokines and cytokine receptors associated with psoriasis found by genome-wide association. (2009) (67)
- Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis (2015) (65)
- Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis. (2009) (65)
- Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. (2013) (64)
- Genetically modified skin to treat disease: potential and limitations. (1994) (64)
- Carriers of rare missense variants in IFIH1 are protected from psoriasis. (2010) (64)
- Stevens-Johnson syndrome associated with Mycoplasma pneumoniae infections. (1978) (63)
- Correlation between keratinocyte expression of Ia and the intensity and duration of contact hypersensitivity responses in mice. (1985) (62)
- Limitations in Screening Instruments for Psoriatic Arthritis: A Comparison of Instruments in Patients with Psoriasis (2013) (60)
- A randomized, double‐blind, placebo‐controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis (2002) (59)
- Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. (2014) (58)
- Isotretinoin treatment of Darier's disease. (1982) (58)
- Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994. (1996) (57)
- Pathogenesis of psoriasis. (1995) (56)
- Work Productivity Loss and Fatigue in Psoriatic Arthritis (2014) (54)
- Clinical Symptoms of Skin, Nails, and Joints Manifest Independently in Patients with Concomitant Psoriasis and Psoriatic Arthritis (2011) (53)
- Biology of Langerhans cells: analysis by experiments to deplete Langerhans cells from human skin. (1984) (53)
- Recurrent staphylococcal abscesses associated with defective neutrophil chemotaxis and allergic rhinitis. (1976) (53)
- The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. (1998) (51)
- The histopathologic evolution of recurrent herpes simplex labialis. (1981) (51)
- Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab (2012) (50)
- Description of the intrafollicular delivery of large molecular weight molecules to follicles of human scalp skin in vitro. (1997) (50)
- Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial. (2006) (49)
- Expression of Ia antigen on epidermal keratinocytes after the grafting of normal skin to nude mice. (1983) (47)
- Cutaneous gene therapy. (1997) (47)
- Efficacy of acitretin and commercial tanning bed therapy for psoriasis. (2003) (46)
- FGF-7 expression enhances the performance of bioengineered skin. (2004) (45)
- Patient-Reported Outcomes and the Association With Clinical Response in Patients With Active Psoriatic Arthritis Treated With Golimumab: Findings Through 2 Years of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (2013) (44)
- Calcifying panniculitis associated with renal failure. A case of Selye's calciphylaxis in man. (1982) (44)
- Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2005) (43)
- Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients. (2012) (42)
- Genetic variations associated with psoriasis and psoriatic arthritis found by genome‐wide association (2010) (42)
- An analysis of select pathogenic messages in lesional and non-lesional psoriatic skin using non-invasive tape harvesting. (2006) (42)
- Outcome measures in psoriatic arthritis. (2007) (41)
- A multicenter, randomized, double-blind trial of tazarotene 0.1% cream in the treatment of photodamage. (2005) (41)
- Drug use and toxicity in psoriatic disease: focus on methotrexate. (2008) (41)
- Seborrheic keratoses: A study comparing the standard cryosurgery with topical calcipotriene, topical tazarotene, and topical imiquimod (2004) (41)
- Psoriasis bench to bedside: genetics meets immunology. (2009) (40)
- In vitro quantitation of cell-mediated immunity in guinea-pigs by macrophage reduction of nitro-blue tetrazolium. (1976) (40)
- Correlation between the inducible keratinocyte expression of Ia and the movement of Langerhans cells into the epidermis. (1985) (39)
- A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. (2009) (39)
- Codeine disposition in human hair after single and multiple doses (1996) (39)
- Kawasaki-like disease in a young adult. Association with primary Epstein-Barr virus infection. (1979) (38)
- Experimental models for psoriasis. (1990) (37)
- Development of a Disease Severity and Responder Index for Psoriatic Arthritis (PsA) — Report of the OMERACT 10 PsA Special Interest Group (2011) (36)
- Development of a Disease Activity and Responder Index for Psoriatic Arthritis — Report of the Psoriatic Arthritis Module at OMERACT 11 (2014) (36)
- Immunology/inflammation of the skin--a 50-year perspective. (1989) (36)
- Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study. (2009) (34)
- Biology of human skin transplanted to the nude mouse: I. Response to agents which modify epidermal proliferation. (1981) (34)
- Diagnosing and treating psoriatic arthritis: an update (2014) (33)
- Quantitative determination of codeine and its major metabolites in human hair by gas chromatography-positive ion chemical ionization mass spectrometry: a clinical application. (1995) (33)
- Local heat urticaria/angioedema: evidence for histamine release without complement activation. (1981) (33)
- A role for epigenetics in psoriasis: methylated Cytosine-Guanine sites differentiate lesional from nonlesional skin and from normal skin. (2012) (33)
- Clindamycin vs placebo as adjunctive therapy in moderately severe acne. (1975) (33)
- Current concepts and review of alefacept in the treatment of psoriasis. (2004) (32)
- The 5q31 variants associated with psoriasis and Crohn's disease are distinct (2008) (32)
- Pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe atopic dermatitis. (2007) (32)
- A multicenter, open‐label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis (2008) (32)
- Fine mapping of eight psoriasis susceptibility loci (2014) (32)
- Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling (2017) (31)
- Regulation of the spatial organization of mesenchymal connective tissue: effects of cell-associated versus released isoforms of platelet-derived growth factor. (1999) (31)
- Detailed genetic characterization of the interleukin-23 receptor in psoriasis (2008) (31)
- Composite Measures in Psoriatic Arthritis: GRAPPA 2008 (2010) (31)
- Mechanism of cortisol inhibition of adoptive transfer of tuberculin sensitivity. (1973) (30)
- Sustained production of human transferrin by transduced fibroblasts implanted into athymic mice: a model for somatic gene therapy. (1995) (29)
- An experimental skin sandwich flap on an independent vascular supply for the study of percutaneous absorption. (1987) (28)
- Lymphocyte suppressor activity in atopic eczema. (1979) (27)
- Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis. (2013) (27)
- A phenomenon of macrophage aggregation activity in sera of patients with exfoliative erythroderma, erythema multiforme, and erythema nodosum. (1973) (27)
- Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis. (2012) (27)
- Immune complexes in the pathogenesis of hypergammaglobulinemic purpura. (1980) (27)
- IgE levels in nummular eczema and ichthyosis. (1973) (26)
- Epidermal proliferation of nude mouse skin, pig skin, and pig skin grafts. Failure of nude mouse skin to respond to the tumor promoter 12- O-tetradecanoyl phorbol 13-acetate (1980) (26)
- A retrospective study of buprenorphine and norbuprenorphine in human hair after multiple doses. (1999) (26)
- Fibroblasts and dermal gene therapy: a minireview. (2000) (24)
- Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting. (2014) (24)
- A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1 (2012) (24)
- Differential suppressive effect of hydrocortisone on lymphocytes and mononuclear macrophages in delayed hypersensitivity of guinea pigs. (1972) (24)
- The development of a rat/human skin flap served by a defined and accessible vasculature on a congenitally athymic (nude) rat. (1985) (23)
- Development of a nude mouse model to study human sebaceous gland physiology and pathophysiology. (1984) (23)
- Biomarkers in Psoriasis and Psoriatic Arthritis: GRAPPA 2008 (2010) (22)
- Differential expression of Ia by murine keratinocytes and gut epithelium in response to recombinant gamma-interferon. (1989) (21)
- Regulation by the skin of lymphoid cell recirculation and localization properties. (1985) (21)
- Purification of Gc-2 globulin from human serum by displacement chromatography: a model for the isolation of marker proteins identified by two-dimensional electrophoresis. (1985) (21)
- The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA (2018) (20)
- Molecular mechanisms in proliferative skin disease. (1976) (20)
- Rosacea induced by beclomethasone dipropionate nasal spray (1999) (20)
- Imaging in Psoriasis and Psoriatic Arthritis: GRAPPA 2008 (2010) (20)
- Thioguanine for refractory psoriasis: a 4-year experience. (2001) (19)
- Using Hawthorne effects to improve adherence in clinical practice: lessons from clinical trials--reply. (2013) (19)
- Disposition of codeine in female human hair after multiple-dose administration. (1995) (19)
- Alefacept in the Treatment of Psoriasis in Patients for Whom Conventional Therapies Are Inadequate (2005) (19)
- Validation of a new international quality-of-life instrument specific to cosmetics and physical appearance: BeautyQoL questionnaire. (2012) (19)
- Persistent transgene expression and normal differentiation of immortalized human keratinocytes in vivo. (1999) (19)
- The dermatology life quality index (DLQI) provides qualitatively different information from the pasi (2004) (18)
- Functional innervation of cultured skin grafts. (1992) (18)
- Cutaneous blood flow and percutaneous absorption: a quantitative analysis using a laser Doppler velocimeter and a blood flow meter. (1989) (17)
- Golimumab Inhibits Progression of Radiographic Damage in Patients with Psoriatic Arthritis: 52 Week Results From the GO-REVEAL Study. (2009) (16)
- Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities (2021) (16)
- Carcinogen metabolism in human skin grafted onto athymic nude mice: a model system for the study of human skin carcinogenesis. (1986) (16)
- Clinical and genetic registries in psoriatic disease. (2008) (15)
- Comparative efficacy of once-daily flurandrenolide tape versus twice-daily diflorasone diacetate ointment in the treatment of psoriasis. (1998) (15)
- Mo1884 Prevalence of Inflammatory Bowel Disease Among Patients With Psoriasis and Incidence of Serious Infections in This Subset: Results From the PSOLAR Registry (2016) (15)
- Role of Epstein-Barr virus in acquired immune deficiency syndrome. (1985) (14)
- A perspective of psoriasis as an aberration in skin modified to expression by the inflammatory/repair system. (1989) (14)
- Biologic aspects of expression of stably integrated transgenes in cells of the skin in vitro and in vivo. (1999) (14)
- Psoriasis therapy--observational or rational? (1993) (13)
- Alteration of HeLa cell growth equilibrium by supernatants of peripheral blood mononuclear cells from normal and psoriatic subjects. (1980) (13)
- Evaluation of triacontanol-containing compounds as anti-inflammatory agents using guinea pig models. (1987) (13)
- Non-Melanoma Skin Cancer Risk Among Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) (2019) (12)
- Anti-native DNA Antibodies in Discoid Lupus Erythematosus (1972) (12)
- Correlation of psoriasis activity with socioeconomic status: cross‐sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) (2018) (12)
- Quantitative analysis of I-α-acetylmethadol, I-α-acetyl-N-normethadol, and I-α-acetyl-N,N-dinormethadol in human hair by positive ion chemical ionization mass spectrometry (1997) (11)
- Description of and treatment to inhibit the rejection of human split-thickness skin grafts by congenitally athymic (nude) rats. (1986) (11)
- Essential Truths for the Care and Management of Moderate-to-Severe Psoriasis. (2015) (11)
- Continuance on etanercept after early incomplete response in patients with psoriasis (2004) (11)
- Use of cyanoacrylate cement in skin grafting congenitally athymic (nude) mice. An improved technique. (1974) (11)
- Induction of dramatic hyperpigmentation in a patient with generalized lichen planus treated with re-PUVA (2002) (11)
- Trigger Factors in Psoriasis (1984) (11)
- A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2 (2012) (11)
- Hair growth in human split-thickness skin grafts transplanted onto nude rats: the role of cyclosporin. (1990) (10)
- The immunobiology of ultraviolet-radiation carcinogenesis. (1985) (10)
- Approach for and assessment of interactive communication via cytokines of cellular components of skin. (1989) (9)
- SAT0561 Persistence of Biologic Therapy in Psoriatic Disease: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) (2015) (9)
- Treatment of Recurrent Herpes Simplex Labialis with Levamisole (1979) (9)
- Defined System to Assess the in Vitro Induction of a Psoriasis Phenotype on Normal Keratinocytes by Fibroblasts from Psoriatic Subjects (1997) (9)
- Tactile function in skin-equivalent grafts (1992) (8)
- Two-dimensional gel electrophoresis can be used to examine chromatographic effluent fractions from displacement column chromatography. (1982) (8)
- Use of cloned genetically modified human fibroblasts to assess long-term survival in vivo. (1997) (8)
- Contact dermatitis from topical auranofin. (1995) (8)
- Alefacept: a novel biologic in the treatment of psoriasis. (2004) (7)
- Impact of pigmentary disorders on quality of life in Japan: Interest of the BeautyQoL instrument (2015) (7)
- Topical auranofin ointment for the treatment of plaque psoriasis. (1995) (7)
- The Remittive Effects of Alefacept (2004) (7)
- PASI 75 [18] (multiple letters) (2005) (7)
- Intermittent short courses of clobetasol propionate ointment 0.05% in the treatment of psoriasis (1987) (6)
- Migration of Langerhans cells and the expression of Ia on epidermal cells following the grafting of normal skin to nude mice. (1984) (6)
- Repeated courses of IM alefacept in psoriasis Rationale and design of an international study that mimics the clinical practice setting (2003) (6)
- A role for humoral factors in psoriasis. (1982) (6)
- Topical agents in the treatment of moderate-to-severe psoriasis (2008) (6)
- Quality of life assessment in cosmetics: specificity and interest of the international BeautyQol instrument (2015) (6)
- The effects of etanercept therapy on patient reported outcomes for patients with moderate to severe psoriasis (2004) (6)
- An in vivo test of viability for cryopreserved human skin. (1986) (6)
- Percutaneous absorption of dexamethasone estimated by a plasma radioimmunoassay. (1976) (6)
- Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis (2021) (6)
- Definitions of Measures of Effect Duration for Psoriasis Treatments (2002) (6)
- Treatment with infliximab is associated with "Major clinical response" in psoriatic arthritis patients treated with infliximab: Analysis of two double-blind placebo controlled trials. (2005) (6)
- Psoriasis and the obesity epidemic: the effect of weight loss. (2013) (5)
- Expression of Natural Resistance in Immune-Deficient Animals (1984) (5)
- Exploring Priority Research Areas in Psoriasis and Psoriatic Arthritis from Dermatologists’ Perspective: A Report from the GRAPPA 2011 Annual Meeting (2012) (5)
- Progress in Diseases of the Skin (1983) (5)
- Comparison of labelling indices of skin involved and uninvolved with psoriasis: Placebo and oral retinoid RO 10-9359 vs. time (1980) (5)
- Dermatologist preferences for treatments to compare in future randomized controlled comparative effectiveness trials for moderate to severe psoriasis. (2012) (5)
- Erratum: Proceedings of the psoriasis combination and rotation therapy conference (Journal of the American Academy of Dermatology (1996) 34 (315- 321)) (1996) (5)
- WITHDRAWN: Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). (2015) (5)
- Anti-native DNA antibodies in discoid lupus erythematosus. (1972) (5)
- Models for studying the cellular processes and barriers to the incorporation of drugs into hair. (1995) (5)
- What the National Psoriasis Foundation means to dermatologists and our patients. (2008) (4)
- Effects of 0.1% retinoic acid on Bateman's actinic purpura. (1995) (4)
- Pathogenesis of psoriasis : current concepts : Psoriasis (1995) (4)
- Assessment of Topical Corticosteroid Bioavailability In Vivo and In Vitro (1993) (4)
- Alefacept to treat psoriasis (2008) (4)
- OP0080 Impact of Persistent Minimal Disease Activity on Long-Term Outcomes in Psoriatic Arthritis: Results from 5 Years of the Long Term Extension of A Randomized, Placebo-Controlled, Study (2014) (4)
- A phenomenon of macrophage aggregation activity in sera of patients with exfoliative erythroderma, erythema multiforme, and erythema nodosum. (1973) (4)
- Evaluation of 1% clindamycin phosphate lotion in the treatment of acne: comparison with 1% clindamycin phosphate solution and lotion placebo (1986) (4)
- Description and definition of a transfollicular route of permeation for topically applied agents to human scalp skin. (1995) (4)
- PSY42 USTEKINUMAB REDUCES ITCH, BODILY PAIN, AND FATIGUE IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS (2009) (4)
- Effect of ultraviolet radiation on Ia expression by keratinocytes. (1989) (3)
- Assessing the Hair Colourings’ Impact on Quality of Life (2015) (3)
- Effect of radio-contrast media on the measurement of adrenal steroids in the urine. (1968) (3)
- Genome-wide association analysis of psoriatic arthritis (2014) (3)
- Doxycycline‐inducible retroviral expression of green fluorescent protein in immortalized human keratinocytes (2002) (3)
- Defining drug‐free remission of skin disease in patients with plaque psoriasis (2019) (3)
- LONG-TERM RADIOGRAPHIC OUTCOME IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GOLIMUMAB : 104 WEEK RESULTS FROM THE GO-REVEAL STUDY (2012) (3)
- Desirable and undesirable cutaneous effects of oral contraceptives. (1977) (3)
- Safety of multiple courses of alefacept in combination with other psoriasis therapies: a study that reflects the clinical practice setting1 (2004) (3)
- Psoriasis Characteristics for the Early Detection of Psoriatic Arthritis (2021) (2)
- PSS41 USTEKINUMAB SIGNIFICANTLY IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS (2008) (2)
- Resistance to 12-0-tetradecanoyl phorbol 13-acetate-induced mitogenesis in the nude mouse. (1984) (2)
- SAT0270 5 Year Safety, Efficacy, and Radiographic Data in Patients with Active Psoriatic Arthritis Treated with Golimumab: Long-Term Extension Results of the Randomized, Placebo-Controlled Study Go-Reveal (2013) (2)
- The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score (2021) (2)
- Quantitative analysis of l-alpha-acetylmethadol, l-alpha-acetyl-N-normethadol, and l-alpha-acetyl-N,N-dinormethadol in human hair by positive ion chemical ionization mass spectrometry. (1997) (2)
- Loss of transgene expression in vivo can be slowed, but not eliminated, by sequestering cells (1998) (2)
- Treatment of Condyloma Acuminatum with Three Different Interferons Administered lntralesionally (2020) (2)
- Desired Improvement Tool (DIT): A tool to assess desire for improvement in psoriasis patients (2015) (2)
- Exacerbation of atopic dermatitis. Production by topical application of retinoic acid. (1972) (2)
- PMS66 EARLY AND SUSTAINED REMISSION ASSOCIATED WITH NORMALIZED PHYSICAL FUNCTION AND HEALTH-RELATED QUALITY OF LIFE AND SIGNIFICANTLY IMPROVED PRODUCTIVITY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH GOLIMUMAB: TWO YEAR DATA FROM THE PHASE III GO-REVEAL CLINICAL TRIAL (2011) (1)
- Selective in vivo immunosuppression in psoriasis (1976) (1)
- Spondylarthropathies (including psoriatic arthritis) 244. Validity of Colour Doppler and Spectral Doppler Ultrasound of Sacroilicac Joints Againts Physical Examination as Gold Standard (2011) (1)
- The Dermatology Foundation: partnerships and programs focused on the future. (2013) (1)
- PSS60 DERMATOLOGY LIFE QUALITY INDEX IS MORE SENSITIVE THAN PSORIASIS AREA AND SEVERITY INDEX TO MEASURE TREATMENT EFFECT IN PATIENTS WITH PSORIASIS: FINDINGS FROM THE PHOENIX I TRIAL (2008) (1)
- PSS29 INTERNATIONAL CO-VALIDATION OF A NEW INTERNATIONAL QUALITY OF LIFE INSTRUMENT SPECIFIC TO PHYSICAL APPEARANCE: BEAUTYQOL (2010) (1)
- Increased Prevalence of Sleep Disorders and Medical Comorbidities in Psoriatic Arthritis Patients Compared with Patients with and without Psoriasis (2011) (1)
- Viral Infections of Athletes' Skin. (1978) (1)
- Psoriatic arthritis and psoriasis: State of the art review and research advances. Epilogue (2005) (1)
- Long-term, continuous dosing of etanercept in patients with plaque psoriasis (2011) (1)
- MONOCYTE CHEMILUMINESCENCE: PHYSICAL AND BIOLOGICAL PARAMETERS (1980) (1)
- Characterizing susceptibility to phenotypic variations of psoriasis by comparing allelic association signals on chromosome 6 (2005) (1)
- Alefacept (human LFA-3/IgG1 fusion protein) is non-immunogenic in two randomized, placebo-controlled phase III trials for chronic plaque psoriasis (2002) (1)
- Systemic corticosteroid use in psoriasis: a national survey of board‐certified dermatologists (2018) (1)
- Differentiation of immortalized human keratinocytes in vivo (1998) (1)
- LYMPHOKINES IN HEALTH AND DISEASE (1977) (1)
- Alefacept: A Viewpoint by Gerald G. Krueger (2003) (1)
- Phosphodiesterase (PDE) Inhibitors for the Treatment of Inflammatory Skin Conditions (2018) (1)
- Psoriasis assessment tools in clinical trials. Discussion (2005) (1)
- OP39. THE CONSEQUENCE OF USING DIFFERENT METHODS OF JOINT ASSESSMENT ON THE ELIGIBILITY FOR ACCESS TO ANTI-TNF IN PSORIATIC ARTHRITIS (2010) (1)
- Impact on the Quality of Life of Two Cosmetic Camouflage Products for Facial Aesthetic Imperfections of Skin Phototypes III and IV : Interest of the Beautyqol Instrument (1)
- Summary of Minutes of the GRAPPA Meeting Adjacent to the American Academy of Dermatology 67th Annual Meeting (2011) (1)
- Alefacept selectively reduces memory-effector (CD45RO+) T cells and improves clinical outcomes in psoriasis and psoriatic arthritis (2002) (1)
- Outcome measures in psoriatic arthritis. (2005) (1)
- Effects of Serum from Normal and Psoriatic Subjects on the Proliferation of Fibroblasts from Involved and Uninvolved Skin of Psoriatic Patients (1997) (1)
- Letter: Familial localized panatrophy: an iatrogenic phenocopy secondary to injection of a corticosteroid. (1976) (1)
- 27876 The PASI-HD improved precision in measuring disease severity in subjects with mild to moderate plaque psoriasis treated with roflumilast cream, a phosphodiesterase-4 inhibitor (2021) (0)
- Resistance of athymic (nude) mouse epidermis and lymphocytes to the tumor promoter, TPA (1982) (0)
- Blood transfusions and psoriasis: is there a link? (2000) (0)
- Changing the Wound Healing Landscape — Offloading Stress , Aiding Stem Cells (2014) (0)
- ELEVATED IL-6 LEVELS ASSOCIATE WITH POOR CLINICAL OUTCOME AND MAY PROMOTE FIBROSIS IN EARLY dcSSc (2011) (0)
- Biology of Langerhans cells: Select: cells into allogeneic and xenogeneui (trafficking/genetic restriction/monoclonal antibodies) (2016) (0)
- Failure of nude mouse skin to respond to the tumor promotor, TPA (1981) (0)
- N12. Psoriasis (1997) (0)
- Spondyloarthropathies (Including Psoriatic Arthritis) [40–69] 40. Eagle's Syndrome: An Unusual Association with Sero-Negative Arthropathy (2010) (0)
- Oral abstracts 1: SpondyloarthropathiesO1. Detecting axial spondyloarthritis amongst primary care back pain referrals (2012) (0)
- 431 Systemic corticosteroid use for psoriasis: A national survey of board-certified dermatologists (2018) (0)
- Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients (2018) (0)
- Specificity of cell mediated immune (CMI) reactions to penicillin homologous protein conjugates (1976) (0)
- Lod heat lJtiicaria/angi'a: Evme for his&ermine r&met uw#Hwwt cmnt activation (1981) (0)
- 529 Profiling of phenotypes and plasma proteins identifies biomarkers for psoriasis severity and psoriatic arthritis (2020) (0)
- CONCISE COMMUNICATION Alefacept therapy produces remission for patients with chronic plaque psoriasis (2003) (0)
- PSS33 INTERNATIONAL DEVELOPMENT OF THE FIRST QUALITY OF LIFE INSTRUMENT SPECIFIC TO COSMETOLOGY AND PHYSICAL APPEARANCE:THE BEAUTYQOL INITIATIVE (2008) (0)
- Characterization of the Psoriasis-associated IL12B and IL23R Genes (2007) (0)
- Diseases of skin and musculo-skeletal systems. (1974) (0)
- Molecular, immunologic, and pharmacologic aspects of psoriasis: Preface (1990) (0)
- Contents, Vol. 183, 1991 (1991) (0)
- 15928 Reduced time to onset of psoriatic arthritis is associated with specific phenotypes and psoriatic characteristics (2020) (0)
- Chemiluminescence by human peripheral blood monocytes responding to phagocytized and nonphagocytized material (1979) (0)
- The society for investigative dermatology: Essential for the future of our specialty (1983) (0)
- 1038 Convergent molecular and histologic profiles of guttate and plaque psoriasis (2019) (0)
- Topical delivery and gene expression of transgenes in human scalp skin in vivo (1998) (0)
- Infliximab therapy results in sustained improvement in functional status and quality of life in patients with psoriatic arthritis - Results from the IMPACT 2 study. (2005) (0)
- Letter: Macrophage-migration inhibition. (1974) (0)
- Sustained improvement in clinical measures of psoriatic arthritis in infliximab-treated patients: 1 year results from impact 2 (2006) (0)
- P099 Topical metronidazole maintains remissions of rosacea (1997) (0)
- Lack of response of athymic (nude) mouse lymphocytes to the tumor promoter, TPA (1981) (0)
- Treatment of Psoriasis (2008) (0)
- Contents, Vol. 179, Supplement 1, 1989 (1989) (0)
- LB802 Whole exome sequencing of 16 psoriasis high-risk pedigrees (2016) (0)
- 213 Initial explorations into genotype-phenotype correlations in psoriasis: The homozygous recessive model (2017) (0)
- Clindamycin Therapy for Moderately Severe Acne-Reply (1976) (0)
- Clindamycin for Acne-Reply (1976) (0)
- Feasibility of Human Skin Grafts on an Isolated but Accessible Vascular Supply on Athymic Rats as a System to Study Percutaneous Penetration and Cutaneous Injury. (1986) (0)
- BSR AND BHPR ORAL PRESENTATION OF ABSTRACTS ORAL ABSTRACTS 1: SPONDYLOARTHROPATHIES (2012) (0)
- PSS30 USTEKINUMAB SIGNIFICANTLY IMPROVES QUALITY OF LIFE IN PATIENTS WITH PSORIASIS: RESULTS FROM A PHASE III STUDY (2008) (0)
- Mononuclear Cell Function and its Relative Potential in the Pathogenesis of Psoriasis* (2019) (0)
- Methods of testing the reaction of various substances on living human skin us patent 4677968. july 7 1987 (1987) (0)
- Insights into the Passive Partitioning of Amino Acids and Codeine into Human Hair (1996) (0)
- Experimental models for psoriasis. (1990) (0)
- Concurrent Oral 6 – Spondylarthropathies [OP40–OP47] OP40. Association of IL23R and IL12B Polymorphisms with Psoriatic Arthritis (2010) (0)
- PSS29 USTEKINUMAB IMPROVES DISEASE SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS: RESULTS WITH THE DERMATOLOGY LIFE QUALITY INDEX (2008) (0)
- Tumor promotion resistance and receptor availability in athymic mouse epidermis (1982) (0)
- Psoriasis options abound. Ongoing research on Enbrel and Raptiva supports their use in psoriasis treatment. (2004) (0)
- Early-Onset Obesity and Risk for Psoriatic Arthritis (2016) (0)
- Characterization of resistance to tpa mitogenesis in the athymic (nude) mouse. Abstr. (1983) (0)
- Alefacept: profile report (2012) (0)
- PSS41 DEVELOPMENT AND ACCEPTABILITY OF A NEW INTERNATIONAL QUALITY OF LIFE INSTRUMENT SPECIFIC TO PHYSICAL APPEARANCE: BEAUTYQOL (2009) (0)
- Book Review Psoriasis (Basic and Clinical Dermatology.) Third edition. Edited by Henry H. Roenigk, Jr., and Howard I. Maibach. 851 pp., illustrated. New York, Marcel Dekker, 1998. $225. 0-8247-0108-9 (1999) (0)
- The authors reply [10] (2007) (0)
- Psoriasis workshop : molecular, immunologic and pharmacologic aspects of psoriasis : Deer Valley, UT, September 14-17, 1989 (1990) (0)
- Development of New and Combined Immune Defects (1984) (0)
- Skin and Psoriasis (2008) (0)
- Taking ovarian cysts to heart (1997) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Gerald G.. Krueger?
Gerald G.. Krueger is affiliated with the following schools:
